Beijing Primegene Therapeutics Co. Ltd. has patented macrocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) allosteric inhibitors reported to be useful for the treatment of neurodegeneration, cancer and autoimmune disease.
Jiangsu Xingsheng Xinhui Pharmaceutical Co. Ltd. has synthesized new membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors that are potentially useful for the treatment of cancer.
An Acerta Pharma BV patent describes new 1-H-pyrrolo[2,3-c]pyridine compounds acting as menin (MEN1)/MLL interaction inhibitors and thus reported to be useful for the treatment of cancer.
Aevisbio Inc. and the Korea Research Institute of Chemical Technology have jointly developed new compounds targeting protein cereblon (CRBN) reported to be useful for the treatment of cancer.
The first patenting from Neuro-Joy Ltd. details development of a device that electrically stimulates facial nerves and muscles in order to emulate a facial expression configured to ameliorate a mood disorder and improve symptoms of depression, anxiety and sleep disorders.
Aliad Biopharma Co. Ltd. has described compounds acting as autophagy inducers and mTOR complex 2 (mTORC2) inhibitors reported to be useful for the treatment of Alzheimer’s disease, among others.
Beijing Konruns Pharmaceutical Co. Ltd. has identified histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
RSS
